



TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

---

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
------------------	---------	-----------	-----------	-----------

---

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>65</b>	<b>65</b>	<b>65</b>	<b>65</b>
<b>Early Deaths</b>				
<b>Moribund Sacrifice</b>	<b>8</b>	<b>7</b>	<b>10</b>	<b>4</b>
<b>Natural Death</b>	<b>12</b>	<b>8</b>	<b>11</b>	<b>8</b>
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	<b>30</b>	<b>35</b>	<b>29</b>	<b>38</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

---

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Inflammation, Chronic Active				1 (2%)
Gallbladder	(38)	(41)	(37)	(43)
Intestine Large, Cecum	(42)	(43)	(40)	(44)
Edema			1 (3%)	
Hemorrhage				1 (2%)
Necrosis			1 (3%)	
Thrombosis			1 (3%)	
Intestine Large, Colon	(44)	(44)	(41)	(46)
Diverticulum				1 (2%)
Intestine Large, Rectum	(45)	(44)	(41)	(47)
Inflammation, Acute			1 (2%)	
Intestine Small, Duodenum	(40)	(43)	(40)	(46)
Edema			1 (3%)	
Inflammation, Chronic			1 (3%)	
Intestine Small, Ileum	(42)	(43)	(40)	(45)
Hemorrhage	1 (2%)			
Hyperplasia, Lymphoid			1 (3%)	
Inflammation, Acute		2 (5%)	2 (5%)	
Inflammation, Chronic Active		1 (2%)		
Necrosis	1 (2%)	1 (2%)	1 (3%)	
Thrombosis			1 (3%)	
Epithelium, Hyperplasia		1 (2%)		
Muscularis, Hyperplasia		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Intestine Small, Jejunum	(40)	(42)	(40)	(44)
Hemorrhage			1 (3%)	
Hyperplasia, Lymphoid	1 (3%)		3 (8%)	
Inflammation, Granulomatous				1 (2%)
Inflammation, Acute		1 (2%)	1 (3%)	
Inflammation, Chronic Active				1 (2%)
Mineralization		1 (2%)		
Necrosis		2 (5%)	1 (3%)	
Muscularis, Hyperplasia		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Amyloid Deposition			1 (2%)	
Angiectasis		1 (2%)	1 (2%)	1 (2%)
Basophilic Focus	2 (4%)	2 (4%)	6 (12%)	4 (8%)
Clear Cell Focus	24 (48%)	23 (46%)	18 (36%)	24 (48%)
Congestion	2 (4%)		1 (2%)	
Cytoplasmic Alteration			1 (2%)	
Eosinophilic Focus	18 (36%)	23 (46%)	26 (52%)	19 (38%)
Fatty Change	1 (2%)		2 (4%)	
Fibrosis		1 (2%)		
Hematopoietic Cell Proliferation	2 (4%)	3 (6%)		3 (6%)
Hemorrhage	2 (4%)		1 (2%)	
Infarct				1 (2%)
Inflammation, Chronic		3 (6%)		2 (4%)
Inflammation, Chronic Active	4 (8%)	7 (14%)	6 (12%)	4 (8%)
Mineralization			1 (2%)	1 (2%)
Mixed Cell Focus	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Necrosis	1 (2%)			2 (4%)
Necrosis, Focal	11 (22%)	10 (20%)	11 (22%)	6 (12%)
Tension Lipidosis		2 (4%)		1 (2%)
Thrombosis		1 (2%)	1 (2%)	2 (4%)
Bile Duct, Cyst	1 (2%)			
Centrilobular, Necrosis	2 (4%)		5 (10%)	1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Kupffer Cell, Hyperplasia			1 (2%)	
Kupffer Cell, Pigmentation	2 (4%)	2 (4%)	4 (8%)	4 (8%)
Oval Cell, Hyperplasia			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Mesentery	(9)	(8)	(11)	(6)
Fibrosis			1 (9%)	
Fat, Necrosis	8 (89%)	8 (100%)	8 (73%)	6 (100%)
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(49)	(45)	(50)
Atrophy	2 (4%)	3 (6%)	5 (11%)	3 (6%)
Cyst	1 (2%)		1 (2%)	1 (2%)
Hemorrhage	1 (2%)			
Hyperplasia, Lymphoid	7 (14%)	12 (24%)	19 (42%)	8 (16%)
Infiltration Cellular, Lipocyte				1 (2%)
Inflammation, Chronic		1 (2%)		
Inflammation, Chronic Active				1 (2%)
Necrosis				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy	1 (2%)		1 (2%)	3 (6%)
Hyperplasia, Lymphoid	36 (72%)	38 (76%)	37 (74%)	40 (80%)
Mineralization	2 (4%)		1 (2%)	
Pigmentation	1 (2%)			
Stomach, Forestomach	(50)	(49)	(48)	(50)
Cyst			1 (2%)	
Edema	3 (6%)	2 (4%)	1 (2%)	
Erosion	1 (2%)	1 (2%)		2 (4%)
Hemorrhage				1 (2%)
Inflammation		1 (2%)		
Inflammation, Acute		1 (2%)		
Inflammation, Chronic	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Inflammation, Chronic Active	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Necrosis	1 (2%)			
Ulcer	9 (18%)	4 (8%)	5 (10%)	5 (10%)
Epithelium, Hyperplasia	11 (22%)	10 (20%)	8 (17%)	10 (20%)
Stomach, Glandular	(48)	(49)	(44)	(49)
Congestion				1 (2%)
Cyst	14 (29%)	19 (39%)	16 (36%)	21 (43%)
Dysplasia			1 (2%)	
Erosion	4 (8%)	3 (6%)	2 (5%)	2 (4%)
Foreign Body	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Hemorrhage	1 (2%)			
Inflammation, Granulomatous	1 (2%)			
Inflammation, Acute		2 (4%)	1 (2%)	2 (4%)
Inflammation, Chronic		1 (2%)	1 (2%)	
Inflammation, Chronic Active		1 (2%)	2 (5%)	
Metaplasia				1 (2%)
Metaplasia, Squamous	3 (6%)		5 (11%)	1 (2%)
Mineralization	1 (2%)	3 (6%)	2 (5%)	8 (16%)
Necrosis		2 (4%)		1 (2%)
Ulcer	1 (2%)		4 (9%)	1 (2%)
Glands, Ectasia	5 (10%)	9 (18%)	5 (11%)	6 (12%)
Glands, Hyperplasia, Cystic				1 (2%)

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(1)	(0)	(0)	(1)
Inflammation, Chronic				1 (100%)
Thrombosis				1 (100%)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	22 (44%)	27 (54%)	28 (56%)	30 (60%)
Inflammation, Acute			3 (6%)	
Inflammation, Chronic Active			1 (2%)	
Mineralization		1 (2%)	3 (6%)	1 (2%)
Thrombosis		2 (4%)	1 (2%)	1 (2%)
Myocardium, Necrosis	2 (4%)		1 (2%)	

**ENDOCRINE SYSTEM**

Adrenal Cortex	(50)	(49)	(47)	(50)
Accessory Adrenal Cortical Nodule	5 (10%)	4 (8%)	1 (2%)	3 (6%)
Degeneration, Hydropic		1 (2%)		
Hyperplasia				1 (2%)
Hypertrophy, Focal	14 (28%)	24 (49%)	17 (36%)	17 (34%)
Necrosis				1 (2%)
Capsule, Hyperplasia	37 (74%)	33 (67%)	36 (77%)	41 (82%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Adrenal Medulla	(49)	(49)	(46)	(50)
Hyperplasia	1 (2%)	4 (8%)	3 (7%)	10 (20%)
Islets, Pancreatic	(50)	(49)	(44)	(50)
Hyperplasia	26 (52%)	33 (67%)	21 (48%)	34 (68%)
Parathyroid Gland	(48)	(48)	(48)	(50)
Amyloid Deposition			1 (2%)	
Cyst	2 (4%)	3 (6%)	3 (6%)	1 (2%)
Pituitary Gland	(50)	(48)	(49)	(50)
Pars Distalis, Cyst		3 (6%)	4 (8%)	2 (4%)
Pars Distalis, Hyperplasia, Focal		1 (2%)	1 (2%)	1 (2%)
Thyroid Gland	(50)	(47)	(46)	(48)
Cyst			1 (2%)	
Hemorrhage			1 (2%)	
Inflammation, Chronic		1 (2%)		
Follicle, Degeneration, Focal	14 (28%)	15 (32%)	20 (43%)	14 (29%)
Follicular Cell, Hyperplasia, Focal		1 (2%)	1 (2%)	1 (2%)

**GENERAL BODY SYSTEM**

Tissue NOS	(2)	(1)	(1)	(0)
Fibrosis	1 (50%)	1 (100%)		
Necrosis	1 (50%)			

**GENITAL SYSTEM**

Coagulating Gland	(0)	(0)	(1)	(0)
Necrosis			1 (100%)	
Epididymis	(49)	(50)	(50)	(50)
Angiectasis	1 (2%)			
Atrophy			1 (2%)	
Fibrosis			1 (2%)	
Granuloma Sperm		2 (4%)		
Inflammation, Chronic	6 (12%)	16 (32%)	14 (28%)	10 (20%)
Necrosis		1 (2%)		
Preputial Gland	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Cyst	2 (4%)	4 (8%)	5 (10%)	6 (12%)
Inflammation, Chronic	16 (32%)	17 (34%)	18 (36%)	18 (36%)
Inflammation, Chronic Active	1 (2%)			
Bilateral, Cyst	1 (2%)			
Prostate	(50)	(49)	(49)	(50)
Fibrosis		1 (2%)		
Infiltration Cellular, Lymphoid	1 (2%)			
Inflammation, Suppurative			1 (2%)	1 (2%)
Inflammation, Chronic	21 (42%)	24 (49%)	23 (47%)	26 (52%)
Necrosis		1 (2%)	1 (2%)	2 (4%)
Seminal Vesicle	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	1 (2%)			
Inflammation, Suppurative			1 (2%)	
Inflammation, Chronic	8 (16%)	10 (20%)	7 (14%)	6 (12%)
Inflammation, Chronic Active		1 (2%)		
Necrosis		1 (2%)	1 (2%)	
Epithelium, Hyperplasia		1 (2%)		
Testes	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)	1 (2%)	
Inflammation, Chronic		1 (2%)		
Mineralization			1 (2%)	
Thrombosis				1 (2%)
Germinal Epithelium, Atrophy	4 (8%)	6 (12%)	5 (10%)	7 (14%)
Interstitial Cell, Hyperplasia		6 (12%)	3 (6%)	

**HEMATOPOIETIC SYSTEM**

Bone Marrow	(50)	(49)	(50)	(50)
Depletion Cellular			1 (2%)	
Hemorrhage			1 (2%)	
Hyperplasia	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Infiltration Cellular, Histiocyte				1 (2%)
Necrosis	1 (2%)		1 (2%)	1 (2%)
Lymph Node	(5)	(6)	(2)	(1)
Hyperplasia, Lymphoid	3 (60%)		1 (50%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Pigmentation	1 (20%)		1 (50%)	
Bronchial, Hyperplasia, Lymphoid		1 (17%)		
Iliac, Hyperplasia, Lymphoid		1 (17%)		
Mediastinal, Ectasia	1 (20%)			
Mediastinal, Hyperplasia, Lymphoid	1 (20%)			1 (100%)
Pancreatic, Hyperplasia, Lymphoid		1 (17%)		
Renal, Hemorrhage		1 (17%)		
Lymph Node, Mandibular	(48)	(48)	(46)	(46)
Atrophy		1 (2%)		
Ectasia	1 (2%)			1 (2%)
Hemorrhage	1 (2%)			
Hyperplasia, Lymphoid	13 (27%)	20 (42%)	14 (30%)	7 (15%)
Inflammation, Granulomatous				1 (2%)
Mineralization				1 (2%)
Lymph Node, Mesenteric	(48)	(47)	(45)	(50)
Angiectasis				1 (2%)
Atrophy	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Congestion	1 (2%)			
Ectasia		2 (4%)		2 (4%)
Hematopoietic Cell Proliferation		1 (2%)		1 (2%)
Hemorrhage	3 (6%)	5 (11%)	7 (16%)	6 (12%)
Hyperplasia, Lymphoid	27 (56%)	30 (64%)	28 (62%)	30 (60%)
Infiltration Cellular, Lipocyte				1 (2%)
Inflammation, Acute			2 (4%)	1 (2%)
Inflammation, Chronic		1 (2%)		
Inflammation, Chronic Active			1 (2%)	
Spleen	(49)	(48)	(45)	(49)
Angiectasis	1 (2%)			
Fibrosis	1 (2%)			
Hematopoietic Cell Proliferation	15 (31%)	16 (33%)	23 (51%)	19 (39%)
Hyperplasia, Lymphoid		2 (4%)	1 (2%)	2 (4%)
Necrosis		1 (2%)	1 (2%)	1 (2%)
Pigmentation	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Lymphoid Follicle, Atrophy		2 (4%)	1 (2%)	
Lymphoid Follicle, Hyperplasia	18 (37%)	25 (52%)	17 (38%)	21 (43%)
Thymus	(48)	(48)	(44)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Cyst	8 (17%)	14 (29%)	13 (30%)	15 (32%)
Hemorrhage			2 (5%)	
Hyperplasia, Lymphoid	3 (6%)	9 (19%)	6 (14%)	3 (6%)
Epithelial Cell, Hyperplasia		1 (2%)		
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)			
Edema				1 (2%)
Erosion			1 (2%)	
Hyperkeratosis	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Infiltration Cellular, Melanocyte		1 (2%)		
Inflammation, Chronic				2 (4%)
Inflammation, Chronic Active		1 (2%)	1 (2%)	
Mineralization		1 (2%)		
Necrosis		1 (2%)		
Ulcer	1 (2%)			
Control, Fibrosis			1 (2%)	
Control, Hyperkeratosis	17 (34%)	24 (48%)	22 (44%)	21 (42%)
Control, Hyperplasia, Melanocyte			1 (2%)	
Control, Inflammation, Acute	1 (2%)			
Control, Inflammation, Chronic	8 (16%)	10 (20%)	13 (26%)	16 (32%)
Control, Vacuolization Cytoplasmic			1 (2%)	
Control, Hair Follicle, Dilatation		1 (2%)		1 (2%)
Control, Subcutaneous Tissue, Hemorrhage		1 (2%)		
Control Epidermis, Hyperplasia	2 (4%)		3 (6%)	3 (6%)
Epidermis, Hyperplasia	1 (2%)			
Epidermis, Site Of Application, Hyperplasia	10 (20%)	7 (14%)	15 (30%)	44 (88%)
Hair Follicle, Site Of Application, Dilatation		1 (2%)	1 (2%)	
Lip, Inflammation, Acute			1 (2%)	
Prepuce, Ulcer		1 (2%)		
Sebaceous Gland, Hyperplasia	1 (2%)			
Sebaceous Gland, Site Of Application, Hyperplasia		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Site Of Application, Erosion				1 (2%)
Site Of Application, Fibrosis		1 (2%)		
Site Of Application, Hemorrhage		1 (2%)		
Site Of Application, Hyperkeratosis	45 (90%)	50 (100%)	49 (98%)	50 (100%)
Site Of Application, Hyperplasia, Melanocyte				19 (38%)
Site Of Application, Inflammation, Acute	1 (2%)	2 (4%)		3 (6%)
Site Of Application, Inflammation, Chronic	13 (26%)	17 (34%)	26 (52%)	43 (86%)
Site Of Application, Ulcer		2 (4%)		2 (4%)
Site Of Application, Vacuolization Cytoplasmic			1 (2%)	1 (2%)

**MUSCULOSKELETAL SYSTEM**

Bone	(50)	(50)	(50)	(50)
Osteopetrosis		1 (2%)		
Cranium, Osteopetrosis	1 (2%)			1 (2%)
Skeletal Muscle	(3)	(2)	(6)	(1)
Angiectasis			1 (17%)	
Degeneration	2 (67%)			
Hemorrhage			1 (17%)	1 (100%)
Inflammation, Chronic		1 (50%)		
Inflammation, Chronic Active	1 (33%)			
Necrosis			1 (17%)	
Capillary, Hyperplasia			1 (17%)	

**NERVOUS SYSTEM**

Brain	(50)	(50)	(50)	(50)
Congestion	1 (2%)	1 (2%)		
Demyelination		1 (2%)		2 (4%)
Gliosis	1 (2%)			1 (2%)
Hemorrhage	4 (8%)	3 (6%)	3 (6%)	5 (10%)
Hyperplasia, Lymphoid	1 (2%)		1 (2%)	1 (2%)
Inflammation, Acute	1 (2%)			
Inflammation, Chronic	1 (2%)			
Necrosis	2 (4%)		3 (6%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Peripheral Nerve Degeneration	(2) 1 (50%)	(1) 1 (100%)	(4) 3 (75%)	(1) 1 (100%)
Spinal Cord	(2)	(1)	(4)	(0)

**RESPIRATORY SYSTEM**

Lung	(50)	(50)	(50)	(50)
Congestion	1 (2%)		2 (4%)	
Fibrosis				1 (2%)
Hemorrhage	7 (14%)	5 (10%)	3 (6%)	4 (8%)
Hyperplasia, Lymphoid	1 (2%)		1 (2%)	
Infiltration Cellular, Histiocyte	13 (26%)	14 (28%)	9 (18%)	13 (26%)
Inflammation, Suppurative	1 (2%)	1 (2%)		1 (2%)
Inflammation, Chronic	1 (2%)			1 (2%)
Metaplasia, Osseous	5 (10%)	1 (2%)		
Mineralization	1 (2%)		1 (2%)	2 (4%)
Thrombosis	4 (8%)	1 (2%)	3 (6%)	2 (4%)
Alveolar Epithelium, Hyperplasia	6 (12%)	9 (18%)	7 (14%)	5 (10%)
Glands, Hyperplasia	1 (2%)			
Nose	(50)	(50)	(50)	(50)
Foreign Body		1 (2%)	2 (4%)	
Hemorrhage	1 (2%)			
Inflammation, Chronic	7 (14%)	11 (22%)	5 (10%)	9 (18%)
Polyp, Inflammatory	2 (4%)	1 (2%)		
Glands, Atrophy				1 (2%)
Goblet Cell, Hyperplasia			1 (2%)	
Respiratory Epithelium, Hyperplasia	1 (2%)	1 (2%)		3 (6%)
Trachea	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Inflammation, Chronic			1 (2%)	
Necrosis			1 (2%)	

**SPECIAL SENSES SYSTEM**

Eye	(48)	(47)	(41)	(47)
-----	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Atrophy	1 (2%)			2 (4%)
Cataract	1 (2%)		1 (2%)	
Inflammation, Chronic	1 (2%)	1 (2%)	2 (5%)	2 (4%)
Inflammation, Chronic Active		1 (2%)		
Cornea, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Lens, Degeneration		1 (2%)		1 (2%)
Harderian Gland	(50)	(49)	(49)	(50)
Hyperplasia, Focal	3 (6%)	6 (12%)	3 (6%)	3 (6%)
Inflammation, Chronic	26 (52%)	23 (47%)	20 (41%)	28 (56%)

**URINARY SYSTEM**

Kidney	(48)	(46)	(42)	(49)
Amyloid Deposition			1 (2%)	
Casts Protein	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Cyst	13 (27%)	13 (28%)	13 (31%)	9 (18%)
Dilatation				1 (2%)
Glomerulosclerosis	1 (2%)		2 (5%)	
Hyperplasia, Lymphoid	34 (71%)	38 (83%)	31 (74%)	36 (73%)
Infarct	3 (6%)	3 (7%)	3 (7%)	4 (8%)
Inflammation, Suppurative	1 (2%)	1 (2%)	3 (7%)	1 (2%)
Inflammation, Chronic				1 (2%)
Metaplasia, Osseous	9 (19%)	3 (7%)	5 (12%)	3 (6%)
Mineralization	17 (35%)	29 (63%)	17 (40%)	31 (63%)
Nephropathy	39 (81%)	41 (89%)	38 (90%)	42 (86%)
Thrombosis			1 (2%)	1 (2%)
Artery, Inflammation, Suppurative	1 (2%)			
Papilla, Necrosis	2 (4%)	2 (4%)		1 (2%)
Pelvis, Dilatation	3 (6%)	3 (7%)	1 (2%)	5 (10%)
Renal Tubule, Accumulation, Hyaline Droplet	1 (2%)			
Renal Tubule, Dilatation, Focal	16 (33%)	15 (33%)	14 (33%)	22 (45%)
Renal Tubule, Dilatation, Diffuse	1 (2%)	1 (2%)	1 (2%)	4 (8%)
Renal Tubule, Hyperplasia				2 (4%)
Renal Tubule, Necrosis	1 (2%)	1 (2%)	2 (5%)	1 (2%)
Renal Tubule, Pigmentation			2 (5%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Transitional Epithelium, Hyperplasia		1 (2%)		1 (2%)
Urethra	(0)	(1)	(2)	(3)
Inflammation, Acute				1 (33%)
Necrosis				2 (67%)
Bulbourethral Gland, Infiltration Cellular			1 (50%)	2 (67%)
Bulbourethral Gland, Necrosis		1 (100%)	1 (50%)	
Transitional Epithelium, Hyperplasia				1 (33%)
Urinary Bladder	(47)	(48)	(42)	(49)
Edema		1 (2%)		2 (4%)
Hemorrhage	1 (2%)			2 (4%)
Hyperplasia, Lymphoid	18 (38%)	22 (46%)	16 (38%)	19 (39%)
Inflammation, Chronic		1 (2%)		2 (4%)
Inflammation, Chronic Active		1 (2%)		
Mineralization			1 (2%)	
Necrosis	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Ulcer				1 (2%)
Muscularis, Degeneration		1 (2%)		
Transitional Epithelium, Hyperplasia	1 (2%)	1 (2%)		2 (4%)

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

---

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
--------------------	---------	-----------	-----------	-----------

---

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>65</b>	<b>65</b>	<b>65</b>	<b>65</b>
<b>Early Deaths</b>				
<b>Accidentally Killed</b>		<b>1</b>		
<b>Moribund Sacrifice</b>	<b>8</b>	<b>7</b>	<b>8</b>	<b>7</b>
<b>Natural Death</b>	<b>3</b>	<b>11</b>	<b>12</b>	<b>13</b>
<b>Survivors</b>				
<b>Natural Death</b>			<b>1</b>	
<b>Terminal Sacrifice</b>	<b>39</b>	<b>31</b>	<b>29</b>	<b>30</b>
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

---

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Hemorrhage			1 (2%)	
Inflammation, Chronic Active				2 (4%)
Gallbladder	(46)	(41)	(39)	(40)
Cyst				1 (3%)
Pigmentation				1 (3%)
Epithelium, Hyperplasia, Adenomatous, Focal				1 (3%)
Intestine Large, Cecum	(47)	(42)	(40)	(42)
Edema	1 (2%)			1 (2%)
Hemorrhage				1 (2%)
Hyperplasia, Lymphoid		1 (2%)		
Intestine Large, Colon	(47)	(44)	(41)	(44)
Edema				1 (2%)
Fibrosis				1 (2%)
Hemorrhage				1 (2%)
Intestine Large, Rectum	(48)	(44)	(40)	(43)
Edema		1 (2%)	1 (3%)	
Hemorrhage				1 (2%)
Inflammation, Acute			1 (3%)	
Inflammation, Chronic Active				1 (2%)
Ulcer			1 (3%)	
Intestine Small, Duodenum	(47)	(42)	(40)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Fibrosis				1 (3%)
Necrosis	3 (6%)			
Epithelium, Hyperplasia	1 (2%)			
Intestine Small, Ileum	(48)	(42)	(40)	(40)
Fibrosis				1 (3%)
Hyperplasia, Lymphoid			1 (3%)	
Inflammation, Acute	1 (2%)	3 (7%)	1 (3%)	1 (3%)
Necrosis	2 (4%)			
Epithelium, Hyperplasia			1 (3%)	
Intestine Small, Jejunum	(47)	(41)	(41)	(40)
Hemorrhage				1 (3%)
Hyperplasia, Lymphoid		1 (2%)		
Inflammation, Acute				1 (3%)
Inflammation, Chronic Active	2 (4%)			
Necrosis	3 (6%)	3 (7%)		
Epithelium, Hyperplasia	1 (2%)			1 (3%)
Liver	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)	1 (2%)	2 (4%)	
Basophilic Focus	1 (2%)	3 (6%)	3 (6%)	
Clear Cell Focus	3 (6%)	2 (4%)	5 (10%)	6 (12%)
Cytoplasmic Alteration, Diffuse	1 (2%)			
Eosinophilic Focus	15 (30%)	23 (46%)	21 (42%)	21 (42%)
Fibrosis				2 (4%)
Hematopoietic Cell Proliferation	4 (8%)	4 (8%)	10 (20%)	1 (2%)
Hemorrhage	2 (4%)			2 (4%)
Infarct		1 (2%)		
Inflammation, Chronic		1 (2%)		1 (2%)
Inflammation, Chronic Active	26 (52%)	32 (64%)	24 (48%)	21 (42%)
Mineralization	1 (2%)	2 (4%)		
Mixed Cell Focus				1 (2%)
Necrosis, Focal	10 (20%)	8 (16%)	11 (22%)	7 (14%)
Tension Lipidosis	1 (2%)		3 (6%)	
Thrombosis		1 (2%)		1 (2%)
Centrilobular, Atrophy, Diffuse			1 (2%)	1 (2%)
Centrilobular, Cytoplasmic Alteration		1 (2%)		
Centrilobular, Degeneration, Granular, Diffuse		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Centrilobular, Necrosis	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Centrilobular, Hepatocyte, Vacuolization Cytoplasmic			1 (2%)	
Hepatocyte, Hypertrophy				1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Hepatocyte, Periportal, Hypertrophy, Diffuse				1 (2%)
Kupffer Cell, Hyperplasia	1 (2%)		1 (2%)	1 (2%)
Kupffer Cell, Pigmentation	4 (8%)	5 (10%)	10 (20%)	4 (8%)
Mesentery	(24)	(25)	(25)	(14)
Fibrosis			2 (8%)	1 (7%)
Inflammation, Chronic	1 (4%)			
Inflammation, Chronic Active			1 (4%)	
Thrombosis	1 (4%)	1 (4%)		
Fat, Necrosis	20 (83%)	23 (92%)	18 (72%)	9 (64%)
Pancreas	(49)	(50)	(46)	(49)
Atrophy	3 (6%)	3 (6%)	5 (11%)	7 (14%)
Cyst			1 (2%)	1 (2%)
Fibrosis				1 (2%)
Hyperplasia	1 (2%)			
Hyperplasia, Lymphoid	27 (55%)	28 (56%)	26 (57%)	25 (51%)
Hyperplasia, Melanocyte				1 (2%)
Hypertrophy	3 (6%)	1 (2%)		2 (4%)
Inflammation, Acute			1 (2%)	1 (2%)
Inflammation, Chronic			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(49)
Atrophy	1 (2%)	1 (2%)	1 (2%)	
Hyperplasia, Lymphoid	47 (94%)	38 (76%)	39 (78%)	38 (78%)
Infiltration Cellular, Lymphoid		1 (2%)		
Mineralization	1 (2%)	1 (2%)		
Artery, Hypertrophy			1 (2%)	
Stomach, Forestomach	(50)	(50)	(47)	(50)
Edema	3 (6%)		1 (2%)	1 (2%)
Erosion	1 (2%)			
Inflammation, Acute	1 (2%)			
Inflammation, Chronic		1 (2%)		1 (2%)
Mineralization		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Necrosis				1 (2%)
Ulcer	4 (8%)	2 (4%)	4 (9%)	1 (2%)
Epithelium, Hyperplasia	4 (8%)	7 (14%)	9 (19%)	3 (6%)
Stomach, Glandular	(49)	(46)	(43)	(47)
Cyst	24 (49%)	24 (52%)	20 (47%)	15 (32%)
Edema	1 (2%)			
Erosion	2 (4%)	1 (2%)		2 (4%)
Fibrosis	1 (2%)			
Hemorrhage			1 (2%)	
Infiltration Cellular, Lipocyte			1 (2%)	
Inflammation, Acute			1 (2%)	
Inflammation, Chronic Active		2 (4%)		1 (2%)
Metaplasia, Squamous		2 (4%)	1 (2%)	
Mineralization	1 (2%)	2 (4%)	3 (7%)	4 (9%)
Necrosis	1 (2%)	1 (2%)		
Pigmentation			1 (2%)	
Ulcer	1 (2%)		1 (2%)	
Epithelium, Dysplasia	1 (2%)			
Epithelium, Hyperplasia	1 (2%)			
Glands, Ectasia	6 (12%)	7 (15%)	6 (14%)	7 (15%)
<b>CARDIOVASCULAR SYSTEM</b>				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	31 (62%)	21 (42%)	19 (38%)	19 (38%)
Mineralization		1 (2%)	3 (6%)	1 (2%)
Thrombosis	2 (4%)		2 (4%)	2 (4%)
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(46)	(50)
Accessory Adrenal Cortical Nodule	4 (8%)	3 (6%)	3 (7%)	5 (10%)
Degeneration, Fatty	3 (6%)		2 (4%)	
Fibrosis				1 (2%)
Hematopoietic Cell Proliferation	1 (2%)	2 (4%)	2 (4%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Hyperplasia, Focal		2 (4%)	2 (4%)	2 (4%)
Hypertrophy, Focal	1 (2%)	1 (2%)		1 (2%)
Infiltration Cellular, Lymphoid		1 (2%)		
Inflammation, Acute		1 (2%)	1 (2%)	
Capsule, Hyperplasia	49 (98%)	48 (96%)	45 (98%)	49 (98%)
Adrenal Medulla	(50)	(48)	(45)	(50)
Hyperplasia	7 (14%)	2 (4%)	6 (13%)	
Islets, Pancreatic	(49)	(50)	(46)	(49)
Hyperplasia	6 (12%)	2 (4%)	2 (4%)	6 (12%)
Parathyroid Gland	(47)	(47)	(44)	(48)
Pituitary Gland	(49)	(47)	(49)	(50)
Thrombosis			1 (2%)	
Pars Distalis, Angiectasis		3 (6%)	5 (10%)	
Pars Distalis, Cyst	1 (2%)	1 (2%)	2 (4%)	
Pars Distalis, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Pars Distalis, Hyperplasia, Focal	7 (14%)	5 (11%)	9 (18%)	5 (10%)
Pars Intermedia, Hyperplasia			1 (2%)	
Pars Intermedia, Hyperplasia, Focal				1 (2%)
Pars Intermedia, Vacuolization Cytoplasmic, Focal	1 (2%)			
Rathke's Cleft, Hemorrhage			1 (2%)	
Thyroid Gland	(49)	(49)	(45)	(48)
Hyperplasia, Lymphoid				1 (2%)
Inflammation, Acute	1 (2%)			
Inflammation, Chronic Active				1 (2%)
Necrosis				1 (2%)
Follicle, Degeneration, Focal	29 (59%)	23 (47%)	27 (60%)	20 (42%)
Follicular Cell, Hyperplasia		1 (2%)		
Follicular Cell, Hyperplasia, Focal	4 (8%)	3 (6%)	5 (11%)	
<b>GENERAL BODY SYSTEM</b>				
Tissue NOS	(3)	(2)	(4)	(0)
Fibrosis		1 (50%)	1 (25%)	
Inflammation, Suppurative	1 (33%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Inflammation, Chronic Active			2 (50%)	

GENITAL SYSTEM

Clitoral Gland	(49)	(48)	(49)	(49)
Inflammation, Chronic	3 (6%)	2 (4%)	2 (4%)	3 (6%)
Ovary	(47)	(49)	(45)	(48)
Angiectasis	4 (9%)	3 (6%)	2 (4%)	
Cyst	4 (9%)	10 (20%)	4 (9%)	10 (21%)
Hemorrhage	12 (26%)	15 (31%)	16 (36%)	11 (23%)
Mineralization		1 (2%)		
Necrosis		1 (2%)		
Thrombosis	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Bilateral, Cyst		1 (2%)		
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	3 (6%)		
Cyst			1 (2%)	
Decidual Reaction		1 (2%)		
Edema		2 (4%)	1 (2%)	
Hyperplasia, Cystic	48 (96%)	45 (90%)	46 (92%)	46 (92%)
Hyperplasia, Lymphoid			1 (2%)	
Inflammation, Suppurative	1 (2%)		9 (18%)	1 (2%)
Inflammation, Histiocytic, Focal			1 (2%)	
Inflammation, Acute		1 (2%)		
Inflammation, Chronic Active			2 (4%)	
Metaplasia, Osseous	2 (4%)			
Necrosis	2 (4%)	3 (6%)	3 (6%)	
Thrombosis		1 (2%)		
Myometrium, Hypertrophy	1 (2%)			
Vagina	(0)	(1)	(1)	(1)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(49)	(50)
Hyperplasia	4 (8%)	1 (2%)	2 (4%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Infiltration Cellular, Histiocyte	2 (4%)		2 (4%)	1 (2%)
Lymph Node	(10)	(7)	(16)	(10)
Ectasia		2 (29%)	6 (38%)	2 (20%)
Hematopoietic Cell Proliferation	1 (10%)			
Hemorrhage		1 (14%)		2 (20%)
Iliac, Ectasia	2 (20%)			1 (10%)
Iliac, Hemorrhage	1 (10%)			
Iliac, Hyperplasia, Lymphoid	4 (40%)			1 (10%)
Mediastinal, Hemorrhage		1 (14%)		
Mediastinal, Hyperplasia, Lymphoid		1 (14%)		
Pancreatic, Hyperplasia	1 (10%)			
Renal, Hyperplasia, Lymphoid	1 (10%)			
Lymph Node, Mandibular	(50)	(48)	(48)	(48)
Atrophy				2 (4%)
Hematopoietic Cell Proliferation	1 (2%)			
Hemorrhage	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hyperplasia, Lymphoid	22 (44%)	14 (29%)	9 (19%)	23 (48%)
Lymph Node, Mesenteric	(45)	(46)	(42)	(49)
Atrophy	2 (4%)	1 (2%)	3 (7%)	1 (2%)
Ectasia	1 (2%)	2 (4%)	3 (7%)	1 (2%)
Fibrosis		1 (2%)		
Hematopoietic Cell Proliferation	3 (7%)			1 (2%)
Hemorrhage	4 (9%)	1 (2%)	2 (5%)	1 (2%)
Hyperplasia, Histiocytic		1 (2%)		
Hyperplasia, Lymphoid	29 (64%)	20 (43%)	21 (50%)	32 (65%)
Necrosis		1 (2%)		
Pigmentation		1 (2%)		
Spleen	(49)	(48)	(44)	(48)
Fibrosis	1 (2%)			1 (2%)
Hematopoietic Cell Proliferation	27 (55%)	31 (65%)	27 (61%)	29 (60%)
Hyperplasia, Lymphoid		3 (6%)	2 (5%)	4 (8%)
Infiltration Cellular, Lymphoid		1 (2%)		
Necrosis			1 (2%)	
Pigmentation	17 (35%)	22 (46%)	19 (43%)	19 (40%)
Lymphoid Follicle, Atrophy		1 (2%)		
Lymphoid Follicle, Hyperplasia	24 (49%)	22 (46%)	18 (41%)	19 (40%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Thymus	(47)	(49)	(44)	(44)
Cyst	10 (21%)	11 (22%)	12 (27%)	7 (16%)
Hemorrhage	9 (19%)	15 (31%)	13 (30%)	10 (23%)
Hyperplasia, Lymphoid	15 (32%)	19 (39%)	13 (30%)	22 (50%)
Hyperplasia, Reticulum Cell			1 (2%)	

**INTEGUMENTARY SYSTEM**

Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	11 (22%)	8 (16%)	8 (16%)	11 (22%)
Inflammation, Chronic			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 (2%)
Edema			1 (2%)	1 (2%)
Hyperkeratosis		1 (2%)		3 (6%)
Hyperplasia, Melanocyte			2 (4%)	2 (4%)
Inflammation, Acute		1 (2%)		
Inflammation, Chronic			1 (2%)	3 (6%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Ulcer				4 (8%)
Control, Edema	1 (2%)		3 (6%)	
Control, Hyperkeratosis	40 (80%)	40 (80%)	39 (78%)	35 (70%)
Control, Hyperplasia, Melanocyte			1 (2%)	
Control, Inflammation, Acute	1 (2%)		1 (2%)	
Control, Inflammation, Chronic	28 (56%)	19 (38%)	26 (52%)	27 (54%)
Control, Necrosis			1 (2%)	
Control, Epidermis, Hyperplasia	1 (2%)		1 (2%)	
Control, Epidermis, Subcutaneous Tissue, Hyperplasia	1 (2%)			
Epidermis, Hyperplasia		1 (2%)	3 (6%)	4 (8%)
Epidermis, Site Of Application, Hyperplasia	7 (14%)	7 (14%)	15 (30%)	34 (68%)
Hair Follicle, Dilatation				1 (2%)
Hair Follicle, Site Of Application, Dilatation			1 (2%)	1 (2%)
Lip, Inflammation, Chronic				1 (2%)
Site Of Application, Erosion	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Site Of Application, Fibrosis		1 (2%)		1 (2%)
Site Of Application, Hyperkeratosis	50 (100%)	49 (98%)	50 (100%)	50 (100%)
Site Of Application, Hyperplasia, Melanocyte	1 (2%)	1 (2%)	3 (6%)	33 (66%)
Site Of Application, Inflammation, Acute	1 (2%)	1 (2%)	2 (4%)	4 (8%)
Site Of Application, Inflammation, Chronic	37 (74%)	36 (72%)	43 (86%)	48 (96%)
Site Of Application, Necrosis				1 (2%)
Site Of Application, Ulcer			3 (6%)	3 (6%)

**MUSCULOSKELETAL SYSTEM**

Bone	(50)	(50)	(50)	(50)
Fibrosis	8 (16%)	9 (18%)	13 (26%)	11 (22%)
Fibrous Osteodystrophy	1 (2%)			
Fracture				1 (2%)
Cranium, Fibrosis	1 (2%)	2 (4%)		
Femur, Fibrosis		3 (6%)	1 (2%)	
Vertebra, Arthrosis			1 (2%)	
Skeletal Muscle	(8)	(3)	(4)	(3)
Degeneration	4 (50%)			1 (33%)
Hemorrhage		1 (33%)		

**NERVOUS SYSTEM**

Brain	(50)	(50)	(50)	(50)
Compression	4 (8%)	2 (4%)	3 (6%)	
Cyst Epithelial Inclusion				1 (2%)
Degeneration	1 (2%)			
Developmental Malformation			1 (2%)	
Gliosis	4 (8%)			1 (2%)
Hemorrhage	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Hyperplasia, Lymphoid	1 (2%)		3 (6%)	1 (2%)
Inflammation, Chronic				1 (2%)
Necrosis	6 (12%)	2 (4%)	4 (8%)	2 (4%)
Thrombosis	1 (2%)			
Meninges, Fibrosis			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Meninges, Inflammation, Chronic		1 (2%)		
Peripheral Nerve	(3)	(2)	(0)	(1)
Degeneration	3 (100%)	1 (50%)		1 (100%)
Spinal Cord	(3)	(2)	(0)	(1)
Degeneration				1 (100%)
Hemorrhage		1 (50%)		
Inflammation, Chronic	1 (33%)			
Necrosis	1 (33%)	1 (50%)		

**RESPIRATORY SYSTEM**

Lung	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			2 (4%)
Hemorrhage	4 (8%)	4 (8%)	4 (8%)	2 (4%)
Hyperplasia, Lymphoid	1 (2%)			
Infiltration Cellular, Histiocyte	6 (12%)	9 (18%)	6 (12%)	2 (4%)
Inflammation, Suppurative				1 (2%)
Inflammation, Chronic	1 (2%)			
Metaplasia, Osseous		1 (2%)	2 (4%)	
Mineralization	1 (2%)		2 (4%)	1 (2%)
Pigmentation			1 (2%)	
Proteinosis	1 (2%)			
Thrombosis			2 (4%)	1 (2%)
Alveolar Epithelium, Hyperplasia	7 (14%)	2 (4%)	1 (2%)	4 (8%)
Nose	(50)	(50)	(50)	(50)
Cyst			1 (2%)	
Hemorrhage	1 (2%)	1 (2%)		1 (2%)
Inflammation, Chronic	6 (12%)	5 (10%)	6 (12%)	5 (10%)

**SPECIAL SENSES SYSTEM**

Eye	(48)	(45)	(43)	(45)
Cataract	1 (2%)			
Inflammation, Acute	1 (2%)			1 (2%)
Inflammation, Chronic	2 (4%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010  
 Time Report Requested: 09:26:54  
 First Dose M/F: 12/13/04 / 12/13/04  
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Inflammation, Chronic Active			1 (2%)	
Necrosis	1 (2%)			
Capillary, Hyperplasia	1 (2%)			
Capillary, Cornea, Hyperplasia			1 (2%)	
Cornea, Hyperplasia	1 (2%)	2 (4%)	1 (2%)	
Retina, Degeneration	1 (2%)			
Harderian Gland	(50)	(50)	(48)	(49)
Hyperplasia				1 (2%)
Hyperplasia, Focal	3 (6%)	4 (8%)	3 (6%)	
Inflammation, Acute			1 (2%)	
Inflammation, Chronic	36 (72%)	39 (78%)	34 (71%)	32 (65%)
Necrosis				1 (2%)

**URINARY SYSTEM**

Kidney	(49)	(46)	(43)	(47)
Casts Protein	4 (8%)		2 (5%)	1 (2%)
Cyst	2 (4%)	1 (2%)	1 (2%)	
Glomerulosclerosis				1 (2%)
Hyperplasia, Lymphoid	43 (88%)	38 (83%)	34 (79%)	38 (81%)
Infarct	5 (10%)	4 (9%)	6 (14%)	3 (6%)
Infiltration Cellular, Lymphoid		2 (4%)		
Metaplasia, Osseous	4 (8%)		2 (5%)	3 (6%)
Mineralization	7 (14%)	6 (13%)	6 (14%)	5 (11%)
Nephropathy	34 (69%)	29 (63%)	28 (65%)	36 (77%)
Papilla, Necrosis				1 (2%)
Pelvis, Degeneration	1 (2%)			
Pelvis, Dilatation	1 (2%)		1 (2%)	1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet	4 (8%)		1 (2%)	2 (4%)
Renal Tubule, Dilatation, Focal	28 (57%)	20 (43%)	19 (44%)	15 (32%)
Renal Tubule, Dilatation, Diffuse		1 (2%)		2 (4%)
Renal Tubule, Hyperplasia	1 (2%)			
Renal Tubule, Necrosis	1 (2%)		1 (2%)	
Renal Tubule, Pigmentation	1 (2%)	2 (4%)		
Transitional Epithelium, Hyperplasia	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 88133 - 08  
Test Type: CHRONIC  
Route: SKIN APPLICATION  
Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Trimethylolpropane triacrylate

CAS Number: 15625-89-5

Date Report Requested: 05/17/2010

Time Report Requested: 09:26:54

First Dose M/F: 12/13/04 / 12/13/04

Lab: SRI

---

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Urinary Bladder	(48)	(48)	(46)	(48)
Hyperplasia, Lymphoid Inflammation, Chronic Active Transitional Epithelium, Hyperplasia	40 (83%)	29 (60%) 1 (2%)	24 (52%) 1 (2%)	31 (65%)

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion